Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma

Hisakazu Nishimori, Nobuharu Fujii, Yoshinobu Maeda, Ken Ichi Matsuoka, Katsuto Takenaka, Katsuji Shinagawa, Kazuma Ikeda, Keitaro Matsuo, Mine Harada, Mitsune Tanimoto

Research output: Contribution to journalArticle

Abstract

Background: The effects of a novel salvage regimen, IDEA (ifosfamide, cytosine arabinoside, etoposide and dexamethasone), which does not include anthracycline or platinum, in patients with non-Hodgkin's lymphoma (NHL) were examined. Patients and Methods: Thirty-four patients with refractory or relapsed NHL were treated with IDEA. Results: The overall remission and complete remission rates were 67.6% and 35.3%, respectively. The toxicity of IDEA was tolerable. With a median follow-up of 14 months, one-year overall survival (OS) and progression-free survival rates were 75.1% and 43.7%, respectively. Adequate numbers of CD34+ cells were obtained in 77.8% of the patients assigned to receive autologous peripheral blood stem cell (PBSC) transplantation. High-dose chemotherapy with autologous PBSC transplantation was carried out in 14 patients; their 3-year OS was 75.0%, with a median follow-up of 38 months. Conclusion: IDEA is an effective secondline chemotherapy regimen for NHL patients and has an excellent PBSC-mobilizing effect.

Original languageEnglish
Pages (from-to)1749-1754
Number of pages6
JournalAnticancer research
Volume29
Issue number5
Publication statusPublished - May 2009

Keywords

  • IDEA
  • Non-Hodgkin's lymphoma (NHL)
  • Salvage

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Nishimori, H., Fujii, N., Maeda, Y., Matsuoka, K. I., Takenaka, K., Shinagawa, K., Ikeda, K., Matsuo, K., Harada, M., & Tanimoto, M. (2009). Efficacy and feasibility of IDEA therapy for refractory or relapsed non-Hodgkin's lymphoma. Anticancer research, 29(5), 1749-1754.